Natco Pharma reports 14.5% decline in net profit at Rs 122 cr for Q1

Drug firm Natco Pharma on Wednesday reported a 14.49 per centdecline in its consolidated net profit to Rs 122.1 crore for the quarter ended June mainly on account of margin pressure on formulations.

The company had posteda net profit of Rs 142.8 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing.

Total income of the company stood at Rs 582.1 crore for the quarter under consideration as against Rs 513.3 crore for the same period year ago, it added.

During the quarter, the company faced margin pressure on both domestic and international formulations, Natco Pharma said.

"In spite of lower margins during the first quarter, the company is confident of its business for remaining part of the financial year based on the order book and earnings outlook. The company expects a growth of over 25 per cent in its earnings for FY2020-21 compared to prior year," it added.

The board of directors has approved an interim dividend of Rs 1.25 per equity share of Rs 2 each for FY2020-21 , the filing said.

Shares of Natco Pharma were trading at Rs843.60per scrip on BSE, down 2.57 per cent over previous close.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel